From clinical trials to clinical practice: Single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma

Therapeutic Advances in Hematology

Volumn 4, Issue 6, 2013, Pages 354-365

  Siegel, David S ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

carfilzomib; drug toxicity; multiple myeloma; proteasome inhibitors

Indexed keywords

ANTIANEMIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ONDANSETRON; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE;

ACUTE KIDNEY FAILURE; ADVERSE DRUG REACTION; ANEMIA; APPLICATION SITE REACTION; BACKACHE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHEST TIGHTNESS; CHILL; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUSHING; HEADACHE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPOTENSION; INFUSION RELATED REACTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG EDEMA; LYMPHOCYTOPENIA; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SIDE EFFECT; SWELLING; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEAKNESS;

EID: 84993791814     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620713511176     Document Type: Review

References (50)

1. Arastu-Kapur S. Anderl J. Kraus M. Parlati F. Shenk K. Lee S. et al. (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 17: 2734–2743.
2. Badros A. (2012) Lenalidomide in myeloma - a high-maintenance friend. N Engl J Med 366: 1836–1838.
3. Badros A. Vij R. Martin T. Zonder J. Kunkel L. Wang Z. et al. (2013) Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 27: 1707–1714.
4. Bringhen S. Federica C. Petrucci M. Gray F. Federico V. Conticello C. et al. (2013) Carfilzomib, cyclophosphamide and dexamethasone(CCD) for newly diagnosed multiple myeloma (MM) patients: initial results of a multicenter, open label phase II study. Haematologica 98(Suppl. 1): abstract S578.
5. Cavaletti G. Jakubowiak A. (2010) Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 51: 1178–1187.
6. Celgene Corporation, Inc. (2013) POMYLAST® Prescribing Information. Celgene Corporation, Inc., Summit, NJ.
7. Clark A. Shetty A. Soutar R. (1999) Renal failure and multiple myeloma: Pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 13: 79–90.
8. DCTD, NCI, NIH and DHHS (2003) Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, 31 March 2003. Available at: http://ctep.cancer.gov (published online 9 August 2006).
9. Demo S. Kirk C. Aujay M. Buchholz T. Dajee M. Ho M. et al. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67: 6383–6391.
10. Dimopoulos M. Richardson P. Brandenburg N. Yu Z. Weber D. Niesvizky R. et al. (2012) A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 119: 2764–2767.
11. Dimopoulos M. Spencer A. Attal M. Prince H. Harousseau J. Dmoszynska A. et al. (2007) Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123–2132.
12. Dimopoulos M. Terpos E. (2010) Multiple myeloma. Ann Oncol 21: vii143-vii150.
13. Faiman B. Mangan P. Spong J. Tariman J. for the International Myeloma Foundation Nurse Leadership Board (2011) Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clin J Oncol Nurs 15(Suppl.): 66–76.
14. Glasmacher A. Hahn C. Hoffmann F. Naumann R. Goldschmidt H. von Lilienfeld-Toal M. et al. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132: 584–593.
15. Harvey R. McCulloch L. (2013) Carfilzomib safety overview from 4 phase 2 studies. Presented at the Hematology / Oncology Pharmacy Association 9th Annual Conference (Los Angeles, CA, 20–23 March 2013), Poster 10.
16. Hazarika M. Rock E. Williams G. Dagher R. Sridhara R. Booth B. et al. (2008) Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. Oncologist 13: 1120–1127.
17. Jagannath S. Barlogie B. Berenson J. Siegel D. Irwin D. Richardson P. et al. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127: 165–172.
18. Jakubowiak A. Dytfeld D. Griffith K. Jasielec J. McDonnell K. Lebovic D. et al. (2013) Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up. J Clin Oncol 31(15 Suppl.): abstract 8543.
19. Kaufman J. Siegel D. Vij R. Ghobrial I. Badros A. Neuman L. et al. (2013) Clinical profile of once-daily, modified-release oprozomib tablets in patients with hematologic malignancies: results of a phase 1b/2 trial. Haematologica 98(Suppl. 1): abstract P233.
20. Kistler K. Rajangam K. Faich G. Lanes S. (2012) Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice. Blood 120: abstract 2916.
21. Knight R. de Lap R. Zeldis J. (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354: 2079–2080.
22. Korde N. Zingone A. Kwok M. Manasanch E. Wu P. Tageja N. et al. (2013) Phase 2 clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) in newly diagnosed multiple myeloma (MM) patients. Haematologica 98(Suppl. 1): abstract P228.
23. Kuhn D. Chen Q. Voorhees P. Strader J. Shenk K. Sun C. et al. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110: 3281–3290.
24. Kumar S. Bensinger W. Reeder C. Zimmerman T. Berenson J. Liu G. et al. (2012) Weekly dosing of the investigational oral proteasome inhibitor MLN 9708 in patients (pts) with relapsed / refractory multiple myeloma (MM): A phase I study. J Clin Oncol 30(15 Suppl.): abstract 8034.
25. Lonial S. Mitsiades C. Richardson P. (2011) Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 17: 1264–1277.
26. Lonial S. Niesvizky R. McCulloch L. Kanya R. Ravi V. et al. (2013) Cardiac and pulmonary safety analysis of single-agent carfilzomib treated relapsed and / or refractory multiple myeloma. Paper presented at the XIVth International Myeloma Workshop (Kyoto, Japan, April 2013), Abstract 413.
27. Martin T. Vij R. Badros A. Patel P. McCulloch L. Jagannath S. (2012) Carfilzomib is associated with a low rate of typically mild to moderate, non-dose limiting treatment-emergent peripheral neuropathy. Haematologica 97: abstract 0857.
28. Mateos M. (2010) Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 36: S24-S32.
29. Mikhael J. Belch A. Prince H. Lucio M. Maiolino A. Corso A. et al. (2009) High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 144: 169–175.
30. Mohty B. El-Cheikh J. Yakoub-Agha I. Moreau P. Harousseau J. Mohty M. (2010) Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 95: 311–319.
31. Moreau P. Pylypenko H. Grosicki S. Karamanesht I. Leleu X. Grishunina M. et al. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12: 431–440.
32. Moreau P. Kolb B. Hulin C. Caillot D. Benboubker L. Tiab M. et al. (2013) CMP–carfilzomib (CFZ) plus melphalan-prednisone (MP)–in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): results of a phase (Ph) I / II trial. Haematologica 98(Suppl. 1): abstract P224.
33. National Comprehensive Cancer Network (NCCN) (2013) Clinical Practice Guidelines in Oncology (NCCN Guidelines). Multiple myeloma. Version 2. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (accessed 8 May 2013).
34. Niesvizky R. Badros A. (2010) Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia. J Natl Compr Canc Netw 8: S13-S20.
35. Onyx Pharmaceuticals, Inc. (2012) KYPROLIS™ Prescribing Information. Onyx Pharmaceuticals, Inc., South San Francisco, CA.
36. Palumbo A. Bladé J. Boccadoro M. Palladino C. Davies F. Dimopoulos M. et al. (2012) How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk 12: 5–11.
37. Papadopoulos K. Lee P. Singhal S. Holahan J. Vesole D. Rosen S. et al. (2011) A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and / or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56mg/m2 expansion cohort of PX-171–007. Blood 118 (21): abstract 2930.
38. Rajkumar S. Blood E. (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354: 2079–2080.
39. Richardson P. Barlogie B. Berenson J. Singhal S. Jagannath S. Irwin D. et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617.
40. Richardson P. Blood E. Mitsiades C. Jagannath S. Zeldenrust S. Alsina M. et al. (2006 a) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108: 3458–3464.
41. Richardson P. Jagannath S. Colson K. (2006 b) Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Clin Adv Hematol Oncol 4(Suppl.): 1; discussion 8.
42. Richardson P. Siegel D. Vij R. Hofmeister C. Jagannath S. Chen C. et al. (2011) Randomized, open label phase 1 / 2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): phase 2 results. Blood. 118: abstract 634.
43. Richardson P. Sonneveld P. Schuster M. Irwin D. Stadtmauer E. Facon T. et al. for the Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487–2498.
44. Siegel D. Martin T. Wang M. Vij R. Jakubowiak A. Lonial S. et al. (2012) A phase 2 study of single-agent carfilzomib (PX-171–003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120: 2817–2825.
45. Siegel D. Martin T. Nooka A. Harvey D. Vij R. Niesvizky R. et al. (2013 a) Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies. Haematologica [ePub ahead of print].
46. Siegel R. Naishadham D. Jemal A. (2013 b) Cancer statistics, 2013. CA Cancer J Clin 63: 11–30.
47. Steurer M. Wagner H. Gastl G. (2004) Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey. Wien Klin Wochenschr 116: 367–372.
48. van de Donk N. Lokhorst H. Dimopoulos M. Cavo M. Morgan G. Einsele H. et al. (2011) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 37: 266–283.
49. Wang M. Martin T. Bensinger W. Alsina M. Siegel D. Kavalerchik E. et al. (2013) Phase 2 dose-expansion study (PX-171–006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood [ePub ahead of print].
50. Weber D. Knight R. Chen C. Spencer S. Yu Z. Zeldis J. et al. (2007) Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma. Blood 110: Abstract 412.